Slide 1: Investor Relations
Investor Relations February 8, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2024 guidance, strategic and growth opportunities, other expectations and other non-historical informa
Slide 3: Our Promise
Our Promise Outcomes. Defined and Delivered. © 2024 Omnicell, Inc. 3
Slide 4: Our Purpose
Our Purpose To be the healthcare providers’ most trusted partner to enable the Autonomous Pharmacy transformation © 2024 Omnicell, Inc. 4
Slide 5: Our Strategy
Our Strategy P R E S C R IBE Omnicell is transforming pharmacy care through outcomes-centric innovation combining robotics, smart devices, intelligent software, and expert services designed D IS P ENS E Point of Care Specialty Pharmacy AS S ES S to optimize clinical and Central Pharmacy Retail busin
Slide 6: What is the Industry Vision of the Autonomous Pharmacy?
What is the Industry Vision of the Autonomous Pharmacy? Zero Medication Zero Medication Zero Human Touches Until Errors Waste Delivery to Patient 100% Regulatory 100% Data & Inventory 100% Pharmacist Time Spent Compliance Visibility on Clinical Activities © 2024 Omnicell, Inc.
Slide 7: The Industry Vision of the Autonomous Pharmacy
The Industry Vision of the o Formation of a collaborative Advisory Board Autonomous o 20 key opinion leaders from US o Published in the American Journal of Health System Pharmacists Pharmacy o Is becoming a standard reference to define the future Replacing manual, error-prone activities with automat
Slide 8: Transforming Medication Management Across All Settings of Care
Transforming Medication Management Across All Settings of Care Robotics Smart Devices Technology designed to automate Streamlining workflows manual tasks to enhance safety expected to achieve pharmacy and optimize labor. and nursing efficiency, putting focus back on care. Software Services Connected
Slide 9: Revenue Growth Drivers
Revenue Growth Drivers Deep Customer Relationships & Robust Multiple Growth Drivers Backlog o Strong position within the top 300 U.S. health systems o Customers increasingly turning to Omnicell for our platform-based approach to medication management o Robust backlog of $1.143 Billion as of 12/31/20
Slide 10: Advanced Services Accelerating Recurring Revenue Growth
Advanced Services Accelerating Recurring Revenue Growth o Leveraging established channels and strong customer relationships Advanced Services (% of Total Revenue) o Demand driven by increasing Targeting 21% of total revenue for 2024 provider digitization and need to evolve medication supply chain 21
Slide 11: Advanced Services Business Model: Customer Example
Advanced Services Business Model: Customer Example Tech-Enabled Services Model (IVCS and CPDS) YEAR 1 YEAR 2 YEAR 3 YEAR 4 – 7 Product Revenue End of year 7 Cash Cash Cash Cash Recurring Advanced Received Received Received Received Net sales type lease Services balance: $0 Revenue Recurring Advanced
Slide 12: Strong Balance Sheet
Strong Balance Sheet $2,227M $1,189M $1,016M As Omnicell reinvests in the transformation to $468M $554M Advanced Services, Free Cash Flow is expected $32M to slow Cash and Cash Equivalents Total Assets Total Equity 1.9x Liquidity and capital structure support $818M 0.7x growth strategy $570M $210M $
Slide 13: Backlog ($Million)
Backlog1 ($Million) By type: As of December 31, 2023 As of December 31, 2022 Product Backlog $611 $797 Advanced Services Backlog2 $532 $418 Total Backlog $1,143 $1,215 By duration and type: As of December 31, 2023 As of December 31, 2022 Short-Term Product Backlog $378 $503 Long-Term Product Backlog
Slide 14: Total Year Revenue Composition
Total Year Revenue Composition Year over Recurring vs YoY Actual Year Actual YoY Guidance GAAP ($Million) Non Category Change % TY-2022 (YoY) TY-2023 Change % TY-2024 Recurring (Mid-Point) Change % Connected Devices, Software Licenses, $828 12% $623 -25% 1 Non Recurring Product & Other $605-$650 -11
Slide 15: Financial Snapshot
Financial Snapshot Q4-2023 Results YoY Change % Total Revenues $259 Million -13% Non-GAAP Gross Margin % 43.6% -170bps Non-GAAP Operating Expenses $103 Million -17% Non-GAAP EBITDA $24 Million -8% Non-GAAP Diluted Earnings Per Share $0.33 0% See Appendix for a reconciliation of Q4-2023 Non-GAAP Gros
Slide 16: 2024 Guidance
2024 Guidance Long-Term Value Creation Opportunities Q1-2024 TY-2024 o Leadership position in the digital Bookings1 Not guided $750 Million -$875 Million transformation of healthcare Total Revenues $232-$242 Million $1.045-$1.120 Billion o Emerging and scaling of Advanced Services offerings Product
Slide 17: A Better Way: Our Environment, Social, Governance, and Innovation Strategy
A Better Way: Our Environment, Social, Governance, and Innovation Strategy Four Pillars of Our Strategy Environment Governance Innovating for Energy Efficiency Doing the Right Thing Actively contribute to realize 1.5° Identify, prevent, and mitigate Celsius future by 2030 risk to Omnicell to create,
Slide 18: A Better Way: Our Approach to ESG
A Better Way: Our Approach to ESG Our Approach o Omnicell uses a risk-based approach designed to strategically align our ESG Our Better Way goals and targets to address the risks we believe are most material to our organization o In 2021, Omnicell identified 11 material topic areas that our internal
Slide 19: A Better Way: ESG in Action
A Better Way: ESG in Action 2022 ESG Environment Social Report o Decreased Scope 1 and 2 emissions in o Finalized creation of four Employee Resource 2022 by 17% from 2021 Groups and established a Global Culture Published third annual ESG Committee Report in April 2023 o Conducted a Climate Risk Asse
Slide 20: We Expect that Omnicell is Positioned to Win Based on Our Belief that:
We Expect that Omnicell is Positioned to Win Based on Our Belief that: Omnicell has the right Omnicell is positioned as Omnicell is scaling With a track record of solutions and the right the leading strategic Advanced Services to strong financial business model to solve partner to health capitalize
Slide 21: Appendix
Appendix
Slide 22: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Reconciliation of GAAP revenues to non-GAAP revenues: GAAP revenues $258,847 $297,674 $1,147,112 $1,295,947 Ac
Slide 23: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Reconciliation of GAAP loss from operations to non-GAAP income from operations: GAAP loss from operations ($23
Slide 24: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Reconciliation of GAAP net income (loss) per share - diluted to non- GAAP net income per share - diluted: Shar
Slide 25: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended Three Months Ended Three Months Ended Three Months Ended Year Ended December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2017 Reconciliation
Slide 26: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Year Ended December 31, 2023 Year Ended December Convertible senior notes, net $ 569,662 31, 2023 Cash and cash equivalents (467,972) Revolver availability $ 350,000 Net debt $ 101,690 C
Slide 27: Omnicell